natgillin/translations-raw huggingface dataset:
In most cases it was not clear if asenapine had been taken sublingually. 
U većini slučajeva nije bilo jasno je li asenapin uzet sublingvalno.
Packs may contain 20, 60 or 100 tablets. 
Pakiranje može sadržavati 20, 60 ili 100 tableta.
Also contact your doctor immediately if any of these conditions develops or worsens while using Sycrest. 
Isto tako, odmah se javite liječniku ako se neko od navedenih stanja pojavi ili pogorša dok uzimate Sycrest.
Other medicines and Sycrest 
Drugi lijekovi i Sycrest
Do not take Sycrest If you are allergic to asenapine or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Sycrest Ako ste alergični na asenapin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Therefore, eating and drinking should be avoided for 10 minutes after administration (see section 4.2). 
Stoga se mora izbjegavati jelo i piće 10 minuta nakon primjene lijeka (vidjeti dio 4.2).
In the early stages of treatment, some people may faint, especially when getting up from a lying or sitting position. 
U ranoj fazi liječenja neke osobe mogu izgubiti svijest, osobito kad ustaju iz ležećeg ili sjedećeg položaja.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije.
Sycrest may cause low blood pressure. 
Sycrest može uzrokovati sniženi krvni tlak.
Following an initial more rapid distribution phase, the terminal half-life of asenapine is approximately 24 h. 
Nakon početne brže faze raspodjele, terminalni poluvijek asenapina iznosi približno 24 h.
Since Sycrest can lower blood pressure, care should be taken when Sycrest is taken with other medicines that lower blood pressure. 
Budući da Sycrest može sniziti krvni tlak, potreban je oprez kad se primjenjuje zajedno s drugim lijekovima koji snižavaju krvni tlak.
Antipsychotic medicines affect the chemicals that allow communication between nerve cells (neurotransmitters). 
Antipsihotici djeluju na spojeve koji omogućuju komunikaciju između živčanih stanica (neurotransmitere).
Sycrest should not be used during pregnancy unless the clinical condition of the woman requires treatment with asenapine and only if the potential benefit outweighs the potential risk to the foetus. 
Sycrest se ne smije uzimati tijekom trudnoće osim ako kliničko stanje žene ne zahtijeva liječenje asenapinom i samo ako moguća korist od liječenja nadilazi mogući rizik za plod.
In elderly patients (between 65 and 85 years of age), exposure to asenapine is approximately 30 % higher than in younger adults. 
U starijih je bolesnika (između 65 i 85 godina) izloženost asenapinu otprilike 30% veća nego u mlađih odraslih osoba.
N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, The Netherlands 
N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, Nizozemska
What you need to know before you take Sycrest 
Što morate znati prije nego počnete uzimati Sycrest
- To ensure optimal absorption, place the tablet under the tongue and wait until it dissolves completely (Figure 3). 
- Kako biste osigurali optimalnu apsorpciju, stavite tabletu pod jezik i pričekajte dok se potpuno ne otopi (Slika 3).
The full therapeutic dose of fluvoxamine would be expected to produce a greater increase in asenapine plasma concentrations. 
Očekuje se da bi puna terapijska doza fluvoksamina izazvala veći porast koncentracije asenapina u plazmi.
Date of first authorisation: 01 September 2010 Date of latest renewal: 05 May 2015 
Datum posljednje obnove odobrenja: 5. svibnja 2015.
If you take too much Sycrest, contact a doctor straight away. 
Ako uzmete previše Sycrest tableta, odmah se javite liječniku.
You should tell your doctor if you are taking medicines for Parkinson's disease (such as levodopa), as this medicine may make them less effective. 
Morate obavijestiti liječnika ako uzimate lijekove za liječenje Parkinsonove bolesti (poput levodope) jer ovaj lijek može umanjiti njihovu učinkovitost.
Asenapine demonstrated superior efficacy to placebo in the reduction of manic symptoms over 3 weeks. 
Asenapin se pokazao djelotvornijim od placeba u smanjivanju maničnih simptoma tijekom tri tjedna.
There is no specific antidote to Sycrest. 
Ne postoji specifični antidot za Sycrest.
If you stop taking Sycrest, you will lose the effects of this medicine. 
Ako prestanete uzimati Sycrest, djelovanje ovog lijeka će se izgubiti.
If your baby develops any of these symptoms you may need to contact your doctor. 
Ako se u Vašeg djeteta pojavi neki od navedenih simptoma, možda ćete se morati javiti liječniku.
Very common side effects (may affect more than 1 in 10 people) - anxiety - sleepiness 
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) - tjeskoba - pospanost
Injury, poisoning and procedural complications 
Ozljede, trovanja i proceduralne komplikacije padovi*
Cerebrovascular events have been reported in patients treated with asenapine but there is no evidence of any excess incidence over what is expected in adults between 18 and 65 years of age. 
U bolesnika liječenih asenapinom prijavljeni su cerebrovaskularni događaji, ali nema dokaza o većoj incidenciji od očekivane u odraslih osoba u dobi od 18 do 65 godina.
Patients from the two pivotal 3 week trials were studied for a further 9 weeks an extension trial. 
Bolesnici iz dva temeljna trotjedna ispitivanja ispitivani su u dodatnom 9-tjednom produžetku ispitivanja.
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000) and not known (cannot be estimated from the available data). 
Sve nuspojave razvrstane su prema organskim sustavima i učestalosti pojavljivanja: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), nepoznato (ne može se procijeniti iz dostupnih podataka).
If you are taking this medicine and you become pregnant or you plan to get pregnant, ask your doctor as soon as possible whether you may continue taking Sycrest. 
Ako uzimate ovaj lijek i zatrudnite ili planirate trudnoću, čim prije upitajte liječnika možete li nastaviti uzimati Sycrest.
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Sycrest. 
Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Sycrest.
Long term efficacy could not be established in a 50-week, uncontrolled, open-label extension trial. 
Dugoročnu djelotvornost nije bilo moguće ustanoviti u 50-tjednom, nekontroliranom otvorenom nastavku ispitivanja.
Asenapine is rapidly distributed and has a large volume of distribution (approximately 20-25 L/kg), indicating extensive extravascular distribution. 
Asenapin se brzo raspodjeljuje i ima velik volumen distribucije (približno 20-25 l/kg), što ukazuje na opsežnu raspodjelu izvan krvnih žila.
- Gently remove the tablet (Figure 2). 
- Pažljivo izvadite tabletu (Slika 2).
Therefore, co-administration of asenapine and fluvoxamine should be approached with caution. 
Stoga se istodobnoj primjeni asenapina i fluvoksamina mora pristupiti s oprezom.
Sycrest sublingual tablets should not be chewed or swallowed. 
Sycrest sublingvalne tablete ne smiju se žvakati niti progutati.
If you miss two or more doses, contact your doctor or pharmacist. 
Ako propustite dvije ili više doza, javite se svom liječniku ili ljekarniku.
In a mass balance study, the majority of the radioactive dose was recovered in urine (about 50 %) and faeces (about 40 %), with only a small amount excreted in faeces (5-16 %) as unchanged compound. 
U ispitivanju masene bilance većina radioaktivno označene doze ustanovljena je u mokraći (oko 50%) i fecesu (oko 40%), dok je samo mali dio (5-16%) izlučen u fecesu u nepromijenjenom obliku.
Asenapine is not indicated for the treatment of children and adolescent patients below 18 years (see section 4.2). 
Asenapin nije indiciran za liječenje bolesnika dječje i adolescentske dobi mlađih od 18 godina (vidjeti dio 4.2).
- The other ingredients are gelatin and mannitol (E421). 
Drugi sastojci su želatina i manitol (E421).
Sycrest is not advised if you are unable to take the tablet as described below. 
Sycrest se ne preporučuje ako ne možete uzeti tabletu na način opisan u daljnjem tekstu.
The table is based on adverse reactions reported during clinical trials and/or post-marketing use. 
Tablica se temelji na nuspojavama prijavljenima u kliničkim ispitivanjima i/ili nakon stavljanja lijeka u promet.
Repeat-dose toxicity studies in rat and dog showed mainly dose-limiting pharmacological effects, such as sedation. 
Ispitivanja toksičnosti ponovljenih doza u štakora i pasa pokazala su uglavnom farmakološke učinke koji ograničavaju dozu, poput sedacije.
Potential for other medicines to affect Sycrest 
Potencijal drugih lijekova da djeluju na Sycrest
Be sure to tell your doctor if you meet any of these conditions as he/she may want to adjust your dose or monitor you for a while. 
Svakako obavijestite liječnika ako se nešto od navedenog odnosi na Vas jer će liječnik možda htjeti prilagoditi dozu ili Vas neko vrijeme nadzirati.
Asenapine is highly bound (95 %) to plasma proteins, including albumin and α1-acid glycoprotein. 
Asenapin se u velikoj mjeri (95%) veže na proteine plazme, uključujući albumin i α1-kiseli glikoprotein.
In case of severe extrapyramidal symptoms, anticholinergic medicines should be administered. 
U slučaju teških ekstrapiramidalnih simptoma se mora primijeniti antikolinergičke lijekove.
Asenapine did not impair fertility in rats and was not teratogenic in rat and rabbit. 
Asenapin nije smanjio plodnost u štakora niti je bio teratogen u štakora i kunića.
Do not breast-feed when taking Sycrest. 
Nemojte dojiti dok uzimate Sycrest.
The incidence of orthostatic hypotension in elderly subjects was 4.1 % compared to 0.3 % in the combined phase 2/3 trial population. 
Incidencija ortostatske hipotenzije u starijih je bolesnika iznosila 4,1%, u usporedbi s 0,3% u populaciji iz kombiniranog ispitivanja faze II/III.
Asenapine may cause somnolence and sedation. 
Asenapin može uzrokovati somnolenciju i sedaciju.
Limited data on efficacy in patients 65 years of age and older are available. 
Podaci o djelotvornosti u bolesnika starijih od 65 godina su ograničeni.
However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death. 
Međutim, stariji bolesnici s demencijom koji se liječe drugim sličnim lijekovima mogu imati povećan rizik od moždanog udara ili smrti.
A statistically significant difference between asenapine and placebo was seen as early as day 2. 
Statistički značajna razlika između asenapina i placeba uočena je već drugog dana.
In subcutaneous carcinogenicity studies in rats and mice, no increases in tumour incidences were observed. 
U ispitivanjima supkutane kancerogenosti u štakora i miševa nije opažen porast incidencije tumora.
You should tell your doctor if you are taking antidepressant medicines (specifically fluvoxamine, paroxetine or fluoxetine), as it may be necessary to change your Sycrest or antidepressant medicine dose. 
Morate obavijestiti liječnika ako uzimate antidepresive (naročito fluvoksamin, paroksetin ili fluoksetin) jer može biti potrebno promijeniti dozu lijeka Sycrest ili dozu antidepresiva.
In addition, histopathological examination of the eyes from dogs treated chronically with asenapine did not reveal any signs of ocular toxicity, demonstrating the absence of a phototoxic hazard. 
Također, histopatološkim pregledom očiju pasa dugoročno liječenih asenapinom nisu otkriveni znakovi toksičnosti za oči, što ukazuje da nema rizika od fototoksičnosti.
Following sublingual administration, asenapine is rapidly absorbed with peak plasma concentrations occurring within 0.5 to 1.5 hours. 
Nakon sublingvalne primjene asenapin se brzo apsorbira, a vršne koncentracije u plazmi postižu se za 0,5 do 1,5 sati.
To ensure optimal absorption, the Sycrest sublingual tablet should be placed under the tongue and allowed to dissolve completely. 
Radi optimalne apsorpcije Sycrest sublingvalnu tabletu se mora staviti pod jezik i pustiti da se u potpunosti otopi.
Patients with rapid cycling were excluded from these studies. 
Bolesnici s brzom izmjenom ciklusa nisu bili uključeni u ova ispitivanja.
If you stop taking Sycrest 
Ako prestanete uzimati Sycrest
If you take more Sycrest than you should 
Ako uzmete više Sycrest tableta nego što ste trebali
However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. 
Međutim, na temelju njegove receptorske farmakologije pretpostavlja se da se djelovanje asenapina odvija kombinacijom antagonističkog djelovanja na receptorima D2 i 5-HT2A.
Therefore, patients should be cautioned about driving and using machines until they are reasonably certain that Sycrest therapy does not affect them adversely. 
Stoga se mora upozoriti bolesnike da budu oprezni prilikom upravljanja vozilima i rada sa strojevima dok nisu sigurni da liječenje lijekom Sycrest na njih ne utječe nepovoljno.
Given the primary effects of asenapine on the central nervous system (CNS) (see section 4.8), caution should be used when it is taken in combination with other centrally acting medicinal products. 
S obzirom na to da asenapin primarno djeluje na središnji živčani sustav (SŽS) (vidjeti dio 4.8), potreban je oprez kad se ovaj lijek uzima u kombinaciji s drugim lijekovima s centralnim djelovanjem.
Asenapine has anaesthetic properties. 
Asenapin ima anestetička svojstva.
Some medicines may reduceor increasethe effect of Sycrest. 
Neki lijekovi mogu umanjiti ili povećati učinak lijeka Sycrest.
MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no 
MSD (Norge) AS Tel: +47 32 20 73 00 msdnorge@msd.no
Furthermore, prolactin-mediated effects on mammary glands and oestrus cycle disturbances were observed. 
Nadalje, opaženi su prolaktinom posredovani učinci na mliječne žlijezde i poremećaji spolnog ciklusa.
Overall mean (SD) weight gain at study endpoint was 3.5 (5.76) kg. 
Sveukupna srednja vrijednost (SD) porasta tjelesne težine na kraju ispitivanja bila je 3,5 (5,76) kg.
In case of overdose you may feel sleepy or tired, or have abnormal body movements, problems with standing and walking, feel dizzy due to low blood pressure and feel agitated and confused. 
U slučaju predoziranja možete biti pospani ili umorni, ili imati nekontrolirane pokrete tijela, poteškoće pri stajanju i hodanju, osjećati omaglicu zbog niskog krvnog tlaka i biti vidno uznemireni i smeteni.
Tell your doctor immediately if you experience involuntary rhythmic movements of the tongue, mouth and face. 
Odmah obavijestite liječnika ako osjetite: - nevoljne ritmične pokrete jezika, usta i lica.
Parkinson's disease and dementia with Lewy bodies Physicians should weigh the risks versus the benefits when prescribing Sycrest to patients with Parkinson's disease or dementia with Lewy Bodies (DLB) since both groups may be at increased risk of neuroleptic malignant syndrome as well as having an increased sensitivity to antipsychotics. 
Parkinsonova bolest i demencija s Lewyjevim tjelešcima Liječnici moraju procijeniti rizike i koristi pri propisivanju lijeka Sycrest bolesnicima s Parkinsonovom bolešću ili demencijom s Lewyjevim tjelešcima jer obje skupine mogu imati povećan rizik za neuroleptički maligni sindrom kao i povećanu osjetljivost na antipsihotike.
A pharmacokinetic study and a short term efficacy and safety study were performed in a paediatric population (ages 10-17 years) with manic or mixed episodes associated with bipolar I disorder. 
Ispitivanje farmakokinetike i ispitivanje kratkoročne djelotvornosti i sigurnosti primjene provedeno je u pedijatrijskoj populaciji (u dobi od 10 do 17 godina) s maničnim ili miješanim epizodama povezanima s bipolarnim poremećajem tipa I.
It is not known whether asenapine or its metabolites are excreted in human milk. 
Nije poznato izlučuju li se asenapin ili njegovi metaboliti u majčino mlijeko.
Sycrest should be used with care in the elderly. 
Sycrest se u starijih osoba mora primjenjivati uz oprez.
Long term safety in this population was explored in a 50-week, open-label, uncontrolled extension study. 
Dugoročna sigurnost primjene u ovoj populaciji ispitana je u 50-tjednom otvorenom, nekontroliranom nastavku ispitivanja.
Therefore, Sycrest is not recommended in such patients. 
Stoga se takvim bolesnicima Sycrest ne preporučuje.
Increasing the dose from 5 to 10 mg twice daily (a two-fold increase) results in less than linear (1.7 times) increases in both the extent of exposure and maximum concentration. 
Povišenje doze s 5 mg na 10 mg dvaput na dan (tj. udvostručenje) rezultira manje nego linearnim povećanjem (1,7 puta) kako stupnja izloženosti tako i najveće koncentracije.
Based on a small pharmacokinetic study, paediatric patients appeared to be more sensitive to dystonia with initial dosing with asenapine when a gradual up-titration schedule was not followed (see section 5.2). 
Na temelju ispitivanja farmakokinetike malog opsega, čini se da su pedijatrijski bolesnici osjetljiviji na distoniju pri početnom doziranju asenapina kada se nije slijedio režim postupnog povećanja doze (vidjeti dio 5.2).
There are no adequate data from the use of Sycrest in pregnant women. 
Nema odgovarajućih podataka o primjeni lijeka Sycrest u trudnica.
NL- 5349 AB Oss The Netherlands 
NL- 5349 AB Oss Nizozemska
Fertility No impairment of fertility has been observed in nonclinical studies (see section 5.3). 
U nekliničkim ispitivanjima nije opažen poremećaj plodnosti (vidjeti dio 5.3).
Increased neonatal mortality was observed among the offspring of female rats treated during gestation and lactation. 
Opažen je povećan neonatalni mortalitet potomaka štakorica koje su dobivale lijek tijekom gestacije i laktacije.
In in vitro assays asenapine acts as an antagonist at these receptors. 
U testovima in vitro asenapin djeluje kao antagonist navedenih receptora.
Asenapine may antagonise the effect of levodopa and dopamine agonists. 
Asenapin može antagonizirati učinak levodope i agonista dopamina.
Asenapine may induce orthostatic hypotension and syncope, especially early in treatment, probably reflecting its α1-adrenergic antagonist properties. 
Asenapin može izazvati ortostatsku hipotenziju i sinkopu, osobito u ranoj fazi liječenja, što je vjerojatno odraz njegovih svojstava kao antagonista α1-adrenergičkih receptora.
What Sycrest contains - The active substance is asenapine. 
Što Sycrest sadrži - Djelatna tvar je asenapin.
Treatment with Sycrest is not advised in patients who are unable to comply with this method of administration, as the bioavailability of asenapine when swallowed is low (< 2 % with an oral tablet formulation). 
Liječenje lijekom Sycrest ne preporučuje se za bolesnike koji se ne mogu pridržavati ovog načina primjene jer je bioraspoloživost asenapina mala kad se proguta (< 2% kod tablete za peroralnu primjenu).
Asenapine has no appreciable affinity for muscarinic cholinergic receptors. 
Asenapin nema značajan afinitet za muskarinske kolinergičke receptore.
In the same study, treatment with paroxetine 20 mg daily decreased the DX/DM ratio to 0.032. 
U istom je ispitivanju liječenje paroksetinom u dozi od 20 mg na dan smanjilo omjer DX/DM na 0,032.
If you do, you should not take Sycrest if you have difficulty controlling core body temperature if you have thoughts of suicide if you have abnormally high levels of prolactin in the blood (hyperprolactinaemia) 
U tom slučaju ne smijete uzimati Sycrest, - ako imate poteškoća s reguliranjem bazalne tjelesne temperature, - ako razmišljate o samoubojstvu, - ako imate neuobičajeno visoke razine prolaktina u krvi (hiperprolaktinemija).
If you forget to take Sycrest 
Ako ste zaboravili uzeti Sycrest
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. 
U nekliničkim ispitivanjima zapaženi su učinci samo pri razinama izloženosti koje su znatno veće od maksimalno dozvoljenih u ljudi, što ukazuje na njihov mali značaj za kliničku primjenu.
The potential effects of inhibitors and an inducer of several of these enzyme pathways on asenapine pharmacokinetics were studied, specifically fluvoxamine (CYP1A2 inhibitor), paroxetine (CYP2D6 inhibitor), imipramine (CYP1A2/2C19/3A4 inhibitor), cimetidine (CYP3A4/2D6/1A2 inhibitor), carbamazepine (CYP3A4/1A2 inducer) and valproate (UGT inhibitor). 
Ispitivani su mogući učinci više inhibitora i jednog induktora nekolicine spomenutih enzimskih putova na farmakokinetiku asenapina, i to fluvoksamina (inhibitor CYP1A2), paroksetina (inhibitor CYP2D6), imipramina (inhibitor CYP1A2/2C19/3A4), cimetidina (inhibitor CYP3A4/2D6/1A2), karbamazepina (induktor CYP3A4/1A2) i valproata (inhibitor UGT).
In rats, embryofoetal toxicity (increased post-implantation loss, decreased foetal weights, and delayed ossification) was observed following oral or intravenous administration during organogenesis or throughout gestation. 
U štakora je embriofetalna toksičnost (povećan gubitak ploda nakon implantacije, smanjena tjelesna masa ploda i zastoj u osifikaciji) opažena nakon peroralne ili intravenske primjene tijekom organogeneze i tijekom cijelog razdoblja gestacije.
Do not cut or tear the blister. 
Nemojte rezati niti trgati blister.
Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. 
Ovisno o kliničkom odgovoru i podnošljivosti u pojedinog bolesnika, doza se može povećati na 10 mg dvaput na dan.
Since Sycrest works primarily in the brain, interference from other medicines(or alcohol) that work in the brain could occur due to an additive effect on brain function. 
Sycrest primarno djeluje na mozak te drugi lijekovi (ili alkohol) koji djeluju na mozak mogu omesti njegovo djelovanje uslijed zbirnog učinka na rad mozga.
Cardiovascular monitoring is necessary to detect possible arrhythmias and management of overdose should concentrate on supportive therapy, maintaining an adequate airway oxygenation and ventilation, and management of symptoms. 
Neophodan je nadzor kardiovaskularnog sustava kako bi se uočile moguće aritmije, a liječenje predoziranja mora se usredotočiti na potpornu terapiju, održavanje odgovarajuće oksigenacije i ventilacije dišnih putova te liječenje simptoma.
Clinical efficacy in bipolar I disorder 
Klinička djelotvornost u bipolarnom poremećaju tipa
Weight increase 
Porast tjelesne težine
Elderly patients with dementia-related psychosis Elderly patients with dementia-related psychosis treated with antipsychotic substances are at an increased risk of death. 
Stariji bolesnici s psihozom povezanom s demencijom Stariji bolesnici s psihozom povezanom s demencijom koji se liječe antipsihoticima imaju povećan rizik od smrti.
Sycrest has not been studied in elderly patients with dementia. 
Sycrest nije ispitivan u starijih bolesnika s demencijom.
If you are taking other medicines, Sycrest should be taken last. 
Ako uzimate i druge lijekove, Sycrest morate uzeti zadnji.
In dogs high oral doses resulted in hepatotoxicity that was not observed after chronic intravenous administration. 
U pasa je peroralna primjena visokih doza dovela do hepatotoksičnosti koja nije opažena nakon dugoročne intravenske primjene.
Additional clinical signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. 
Dodatni klinički znakovi mogu biti mioglobinurija (rabdomioliza) i akutno zatajenje bubrega.
Transient, asymptomatic elevations of hepatic transaminases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment. 
Često su zabilježena prolazna asimptomatska povišenja vrijednosti jetrenih transaminaza, alanin transferaze (ALT) i asparat transferaze (AST), osobito u ranoj fazi liječenja.
Asenapine was not teratogenic in animal studies. 
Asenapin nije bio teratogen u ispitivanjimana životinjama.
Asenapine is extensively metabolized. 
Asenapin se opsežno metabolizira.
Sycrest may cause sleepiness or sedation. 
Sycrest može uzrokovati pospanost ili sedaciju.